You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

CLINICAL TRIALS PROFILE FOR SORBITOL 3.3% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Sorbitol 3.3% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000159 ↗ Sorbinil Retinopathy Trial (SRT) Completed National Eye Institute (NEI) Phase 3 1983-08-01 To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00121433 ↗ Leptin and Endothelial Function Completed Amgen Phase 4 2004-09-01 The purpose of this trial was to determine if injections of leptin would improve vascular function in normal-weight, healthy volunteers.
NCT00121433 ↗ Leptin and Endothelial Function Completed University of Michigan Phase 4 2004-09-01 The purpose of this trial was to determine if injections of leptin would improve vascular function in normal-weight, healthy volunteers.
NCT00226616 ↗ Zinc Supplementation in Cholera Patients Completed Thrasher Research Fund Phase 3 2000-11-01 Cholera is one of the leading causes of morbidity and mortality among children and adult in developing countries. We will evaluate the effect of supplementation of zinc on reduction of duration and severity of cholera. Since cholera is primarily a disease of older children and adults, we intend to study the effects of zinc supplementation among children of 3 to 14 years of age, whose initial stool weight will be >4ml/kg/hour in 1st 6 hours and dark field examination is positive. 90 subjects in each group hospitalized with cholera with diarrhea for less than 24 hours will be selected. After inclusion in the study, informed consent will be obtained from guardian explaining the full procedure in the hospital. The subjects will be randomized to receive either zinc or placebo until diarrhea resolves. History of illness and baseline information will be collected in the hospital through interview, which may take duration of 10 minutes.After 6 hours of initial rehydration, fluid balance study will be carried out on all subjects until diarrhea resolves. 1 ml (1/4 teaspoonful) of blood sample will be taken to assess serum zinc level on admission after initial hydration and will be repeated on the day of recovery. This procedure carries a small risk of infection if not done under sanitary conditions; however, we will maintain proper sanitation, so there is no risk in the procedures. There is no potential risk in this study.20mg elemental Zinc will be given daily in 2 divided doses till cholera resolves. Both groups will receive syrup or tablet Erythromycin 50mg/kg/24 in 4 divided doses for 3 days. Oral rehydration solution/intravenous acetate fluid will be used for rehydration. Daily body weight will be taken and stool will be sent for C/S until the day of recovery or 5 days. Zinc loss in stool will be seen in 20% of random stool samples. Information obtained from history and the laboratory investigations of subject will be kept strictly confidential and no one other than the investigators of this study and the Ethics Committee of this Centre will/ has access to the information. The study will benefit the patients as study physician will do close observation, examination and will take care frequently, as research staff will monitor systematic progress and take necessary action. Study micronutrient (zinc) is shown to have benefit in children in acute diarrhea. If the results of the study is positive, it will benefit the patients in their treatment during this study and thereafter. The data will be analyzed for clinical effects of zinc on diarrhea.The study will help to improve the treatment strategy of cholera in children. The study will use hospital records, which will be returned after completion of the study. Stool, urine and 1 ml (1/4 teaspoonful) of venous blood will be taken to assess serum zinc level.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sorbitol 3.3% In Plastic Container

Condition Name

Condition Name for Sorbitol 3.3% In Plastic Container
Intervention Trials
Constipation 2
Intoxication 2
Severe Mental Illness 2
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sorbitol 3.3% In Plastic Container
Intervention Trials
Tooth Diseases 3
Nerve Compression Syndromes 3
Hereditary Sensory and Motor Neuropathy 3
Charcot-Marie-Tooth Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sorbitol 3.3% In Plastic Container

Trials by Country

Trials by Country for Sorbitol 3.3% In Plastic Container
Location Trials
United States 27
China 5
Ukraine 4
Turkey 4
Moldova, Republic of 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sorbitol 3.3% In Plastic Container
Location Trials
New York 3
Kansas 3
California 3
Washington 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sorbitol 3.3% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Sorbitol 3.3% In Plastic Container
Clinical Trial Phase Trials
Phase 4 10
Phase 3 6
Phase 2/Phase 3 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sorbitol 3.3% In Plastic Container
Clinical Trial Phase Trials
Completed 16
Recruiting 9
Not yet recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sorbitol 3.3% In Plastic Container

Sponsor Name

Sponsor Name for Sorbitol 3.3% In Plastic Container
Sponsor Trials
Yuria-Pharm 4
Sahlgrenska University Hospital, Sweden 3
ScandiBio Therapeutics AB 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sorbitol 3.3% In Plastic Container
Sponsor Trials
Other 48
Industry 19
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sorbitol 3.3% in Plastic Container: Clinical Trials, Market Analysis, and Projections

Introduction to Sorbitol

Sorbitol, also known as D-sorbitol or D-glucitol, is a carbohydrate that belongs to the class of sugar alcohols or polyols. It is widely used in various industries, including food, cosmetics, pharmaceuticals, and medical procedures. Here, we will focus on the clinical trials, market analysis, and projections specifically for Sorbitol 3.3% in Plastic Container.

Clinical Trials and Medical Use

Urologic Irrigation

Sorbitol 3% or 3.3% solutions in plastic containers are commonly used as urologic irrigating fluids. These solutions are sterile, nonpyrogenic, and nonhemolytic, making them ideal for endoscopic procedures and maintaining the patency of indwelling catheters. During transurethral surgical procedures, sorbitol solutions act as a lavage to remove blood and tissue fragments, providing high visibility due to their non-conductive properties[1][4].

Other Medical Uses

Sorbitol is also used in other medical contexts, such as a laxative and in diagnostic agents. However, the specific formulation of 3.3% sorbitol in plastic containers is primarily associated with urologic procedures.

Clinical Trials

While there are numerous clinical trials involving sorbitol, the specific trials related to Sorbitol 3.3% in Plastic Container are not extensively detailed in recent literature. However, general clinical trials on sorbitol often focus on its safety, efficacy, and metabolic impact. For instance, the Phase 3 INSPIRE trial by Applied Therapeutics evaluates the effect of a drug on sorbitol dehydrogenase (SORD) deficiency, showing significant reduction in sorbitol levels, but this is not directly related to the 3.3% solution in plastic containers[3].

Market Analysis

Market Size and Growth

The sorbitol market, including all its forms and applications, is projected to grow significantly. By 2027, the sorbitol market is estimated to reach $2.3 billion, growing at a CAGR of 5.2% from 2022 to 2027[2].

Segment Analysis

The liquid-based segment of the sorbitol market, which includes the 3.3% solution, held a significant share in 2021 and is expected to grow at a CAGR of 5.1% during the forecast period. This growth is driven by the increasing demand for sorbitol as a sugar substitute in consumer food products and its use in pharmaceuticals and personal care products[2].

Impact of COVID-19

The COVID-19 pandemic has influenced consumer behavior, leading to increased demand for health-conscious food products. This shift has driven the demand for low-calorie and low-sugar alternatives, including sorbitol. However, the pandemic also disrupted supply chains, affecting manufacturers' consumption patterns and investment plans[5].

Market Projections

Forecast Period

By 2029, the sorbitol market is expected to reach $1.75 billion, growing at a CAGR of 6.56% from 2025 to 2030. This growth is attributed to the increasing awareness of the health benefits of low-calorie and low-sugar products, as well as the versatility of sorbitol in various industries[5].

Industry Trends

The market is driven by the growing demand for sorbitol in food, beverages, and pharmaceuticals. Sorbitol's role as a sweetener, humectant, texturizer, and stabilizer makes it a crucial ingredient in many products. The trend towards healthier lifestyles and the need for sugar substitutes continue to fuel the market growth[2][5].

Key Takeaways

  • Clinical Use: Sorbitol 3.3% in Plastic Container is primarily used as a urologic irrigating fluid, offering nonhemolytic and non-conductive properties essential for endoscopic procedures.
  • Market Growth: The sorbitol market is expected to grow significantly, driven by increasing demand for low-calorie and low-sugar products.
  • Segment Analysis: The liquid-based segment, which includes the 3.3% solution, is a significant contributor to the market growth.
  • COVID-19 Impact: The pandemic has influenced consumer behavior, driving demand for health-conscious products but also disrupting supply chains.

FAQs

What is Sorbitol 3.3% in Plastic Container used for?

Sorbitol 3.3% in Plastic Container is used as a urologic irrigating fluid during endoscopic procedures and for maintaining the patency of indwelling catheters.

How does the COVID-19 pandemic affect the sorbitol market?

The COVID-19 pandemic has increased demand for low-calorie and low-sugar products, driving the market growth, but it has also disrupted supply chains and affected manufacturers' operations.

What are the key drivers of the sorbitol market growth?

The key drivers include the growing demand for sorbitol as a sugar substitute, its use in pharmaceuticals and personal care products, and the increasing awareness of health benefits associated with low-calorie and low-sugar products.

What is the projected market size of the sorbitol market by 2029?

The sorbitol market is expected to reach $1.75 billion by 2029, growing at a CAGR of 6.56% from 2025 to 2030.

What are the common applications of sorbitol besides medical use?

Sorbitol is widely used as a sweetener, humectant, texturizer, and stabilizer in food, beverages, cosmetics, and pharmaceuticals.

Sources

  1. Meadows Medical: Baxter 3% Sorbitol Urologic Irrigating Solution 3000 mL UROMATIC Plastic Container.
  2. IndustryARC: Sorbitol Market Size Report, 2022-2027.
  3. Applied Therapeutics: Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency.
  4. PharmaKB: Sorbitol - PharmaKB.
  5. Mordor Intelligence: Sorbitol Market - Size, Share & Analysis.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.